doctor reading the record of a patient's condition
Hymovis

Content prepared by Direct Doctor Supply’s Editorial team.


Last Updated On September 25, 2026

Hymovis Prescribing Information for Practitioners

Nov 22, 2024

Viscosupplements are widely prescribed for osteoarthritis, benefiting millions of patients by relieving pain and improving joint function. These treatments, including hyaluronic acid injections, lubricate and cushion the joints, significantly easing osteoarthritis symptoms and improving mobility.

Hymovis is a leading viscosupplement specifically formulated to address knee pain caused by osteoarthritis. It is often recommended for patients who have not found relief with other arthritis treatments. Its unique formulation ensures long-lasting relief, making it a valuable option for managing osteoarthritis symptoms.

This article provides a comprehensive guide for practitioners on the Hymovis prescribing information, including proper dosage, administration techniques, and potential side effects.

Key Takeaways

  • Hymovis is a viscosupplement designed to relieve knee osteoarthritis pain and improve mobility.
  • The recommended dosage involves two 3 mL injections spaced one week apart, providing up to six months of symptom relief.
  • Contraindications include allergies to hyaluronan, infections near the injection site, and certain medical conditions like bleeding disorders.
  • Hymovis offers long-lasting pain relief due to its advanced HYADD®4 formulation, which enhances joint lubrication and shock absorption.
  • Managing side effects involves basic measures such as applying ice packs, rest, and maintaining cleanliness at the injection site.
  • Patient suitability depends on overall health, the severity of osteoarthritis, and prior responses to first-line treatments.
HYMOVIS 01
HYMOVIS® (German)

$ 629.00
Add To Cart
–+
NEOPHARMED SUPARTZ ITALIAN 5X2.5ML 01
SUPARTZ® (Italian)

$ 319.00
Add To Cart
–+

About: Trusted by over 2,000+ global clients since 2014, Direct Doctor Supply has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Direct Doctor Supply offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world.

Hymovis Prescribing Information: Dosage and Administration Techinques

Hymovis is an intra-articular injection that can treat knee osteoarthritis. The recommended dosage is two injections of 3 mL each, spaced one week apart. This regimen provides long-lasting pain relief and improved joint mobility, often for up to six months. Healthcare professionals, clinics, and eligible buyers looking to buy Hymovis online can explore product availability through Direct Doctor Supply, which provides access to a range of medical and healthcare products.

right dose of medication

Administration Technique

  • A healthcare professional should administer the injection directly into the knee joint’s synovial space under aseptic conditions.
  • Before injecting Hymovis, aspirate any effusion present in the knee to ensure optimal effectiveness. This process can be done with an 18-20 gauge needle.
  • To minimize infection risk, experts should use standard intra-articular injection site preparation and strict aseptic technique.

Contraindications, Warnings, and Precautions

Before administering Hymovis for knee osteoarthritis, practitioners should review the Hymovis prescribing information and consider relevant contraindications, warnings, and precautions to ensure patient safety:

  • Allergy to Hyaluronan: Patients allergic to Hymovis ingredients such as hyaluronan or bacterial fermentation products should not receive Hymovis.
  • Infection: Avoid injection if there is a knee infection, open wound, or skin condition near the site, as this may worsen the infection.
  • Pregnancy & Breastfeeding: Hymovis is not recommended due to insufficient safety data for pregnant or breastfeeding women.
  • Pediatric Use: It is not approved for patients under 18 years old.
  • Bleeding Disorders: Doctors should exercise caution before administering the treatment in patients with bleeding problems, as intra-articular injections may increase the risk of bleeding.
  • Knee Malformation: Structural abnormalities or severe muscle weakness may affect Hymovis distribution and effectiveness.
  • Sterile Technique: A clean injection site is critical to minimize infection risk.
  • Monitoring Side Effects: Healthcare providers should inform their patients about potential side effects, including swelling or discomfort at the injection site, which typically resolve within days.

Patient Selection Criteria and Expected Outcomes

Hymovis is an effective treatment option for knee osteoarthritis (OA), particularly for patients who have not experienced sufficient relief from first-line therapies such as physical therapy, oral analgesics, or nonsteroidal anti-inflammatory drugs (NSAIDs). It is recommended for individuals with mild to moderate OA who want to reduce joint pain and stiffness.

patient's knee checkup

Ideal candidates for Hymovis include those without active knee infections, significant structural abnormalities, or known hyaluronan allergies. Patients with bleeding disorders or those on anticoagulants should undergo careful evaluation to ensure the treatment’s safety. Healthcare providers should review the Hymovis prescribing information before treatment to confirm contraindications, administration guidelines, and other important safety considerations. By focusing on the patient’s overall health and condition, healthcare providers can identify individuals most likely to benefit from the therapy.

Hymovis delivers long-lasting pain relief, with benefits often extending up to six months after completing its two-dose injection regimen. Thanks to its advanced HYADD®4 formulation, the treatment enhances the viscoelastic properties of synovial fluid, improving shock absorption and reducing joint friction. Many patients report significant reductions in knee pain and stiffness, leading to better mobility and improved performance in daily activities.

To optimize outcomes, set realistic expectations. While Hymovis effectively alleviates symptoms, it does not reverse cartilage damage or cure osteoarthritis. Patients should understand that results vary; some experience noticeable relief within weeks, while others need more time to improve.

Encouraging patients to follow a comprehensive OA management plan can further enhance the benefits of Hymovis. Recommendations may include weight management, low-impact exercises, and adherence to post-treatment guidelines. Regular follow-up appointments allow providers to monitor progress, address concerns, and keep treatment aligned with the patient’s goals, leading to greater satisfaction and long-term success.

2026 Study Update: HYMOVIS® ONE Shows Sustained Knee OA Pain Relief

A 2026 randomized, double-blind, multicenter study evaluated HYMOVIS® ONE in 347 patients with knee osteoarthritis. Researchers found that walking pain decreased by 65% at week 12 and 73% at week 26 following a single HYMOVIS® ONE injection. They also observed improvements in stiffness, physical function, health-related quality of life, and other clinical outcomes. At 26 weeks, HYMOVIS® ONE remained non-inferior to another hyaluronic acid formulation, while both treatments were well tolerated. These findings provide recent evidence supporting sustained symptomatic relief following HYMOVIS® ONE treatment for knee osteoarthritis.[3]

Guidelines for Managing Treatment Side Effects

Managing side effects from Hymovis injections is crucial for ensuring patient comfort and successful outcomes. Although the treatment is generally well-tolerated, minor side effects may occur. Understanding the Hymovis injection ingredients, particularly the formulation administered into the joint, can help healthcare professionals provide appropriate guidance and set realistic expectations about potential reactions. Here are guidelines for addressing common reactions:

doctor checks the state of a patient's knee
  • Discomfort at the Injection Site: Apply an ice pack in brief intervals immediately after the injection to reduce pain and swelling.
  • Knee Inflammation: Encourage patients to rest and elevate the leg to minimize swelling.
  • Localized Redness or Swelling: To prevent irritation, keep the injection site clean and cover it with a clean bandage if needed.
  • Joint Stiffness: Recommend gentle, low-impact exercises to improve mobility and reduce stiffness.
  • Mild Skin Irritation: Over-the-counter creams can help soothe minor irritation at the injection site.
  • Temporary Discoloration: Assure patients that bruising or redness is common and typically resolves within a week.
  • Warmth Around the Treated Area: Suggest using a cold compress to alleviate discomfort.

Conclusion

Hymovis injections provide a clinically proven option for managing knee osteoarthritis pain, particularly for patients who have not responded adequately to first-line treatments. With its advanced formulation, Hymovis helps improve joint lubrication and reduce friction, potentially improving mobility and quality of life. Before treatment, practitioners should review the Hymovis prescribing information to confirm appropriate administration, assess patient suitability, monitor potential side effects, and set realistic expectations for treatment outcomes.

Combined with a comprehensive osteoarthritis management plan, Hymovis can be an effective option for patients seeking long-term pain relief and improved joint function.

FAQs

1. Can Hymovis cure osteoarthritis?

Hymovis cannot cure osteoarthritis or reverse cartilage damage. It can alleviate symptoms and improve mobility by enhancing joint lubrication.

2. How soon can patients experience relief after Hymovis injections?

Some patients may notice improvements within weeks, while others may take longer to experience significant relief. Results typically last up to six months.

3. Who is not eligible for Hymovis treatment?

Patients with allergies to hyaluronan, active knee infections, or significant structural joint abnormalities are not suitable candidates for Hymovis. It may also not work for individuals under 18, pregnant or breastfeeding women, and those with bleeding disorders.

Need help, additional info, or customized deals?

Talk with our sales representative.

Book a Meeting

Citations

[1] Viscosupplementation for Osteoarthritis. Accessed 22 Nov. 2024. https://assets.ctfassets.net/plyq12u1bv8a/5D6hhWQpECcNeI2e6VG567/2baa3d83abb82476d2eede90d1afc5e3/CG054_Viscosupplementation_for_Osteoarthritis.pdf.

[2] Knee Pain – Symptoms and Causes. Mayo Clinic, 2019. https://www.mayoclinic.org/diseases-conditions/knee-pain/symptoms-causes/syc-20350849.

[3] Ruosi, C., et al. “Single-Injection Hyaluronic Acid Treatment Demonstrates Non-Inferiority in the Relief of Symptomatic Knee Osteoarthritis: A Randomized Double-Blind, Multi-Center Controlled Study.” Osteoarthritis and Cartilage Open, vol. 8, no. 2, 5 Feb. 2026, p. 100752. doi:10.1016/j.ocarto.2026.100752. PubMed. Accessed 25 Sept. 2026.

Sourcing and accuracy for this article follow our Editorial policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published